Wave Life Sciences Ltd [WVE] stock is trading at $9.97, up 0.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The WVE shares have gain 4.84% over the last week, with a monthly amount glided 21.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Wave Life Sciences Ltd [NASDAQ: WVE] stock has seen the most recent analyst activity on August 04, 2025, when Canaccord Genuity initiated its Buy rating and assigned the stock a price target of $19. Previously, Oppenheimer started tracking the stock with Outperform rating on July 28, 2025, and set its price target to $24. On July 16, 2025, Citigroup initiated with a Buy rating and assigned a price target of $16 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $10 as its price target on April 29, 2025. Wedbush started tracking with a Outperform rating for this stock on April 08, 2025, and assigned it a price target of $18. In a note dated February 25, 2025, Jefferies initiated a Buy rating and provided a target price of $26 on this stock.
Wave Life Sciences Ltd [WVE] stock has fluctuated between $5.04 and $16.74 over the past year. Currently, Wall Street analysts expect the stock to reach $22.14 within the next 12 months. Wave Life Sciences Ltd [NASDAQ: WVE] shares were valued at $9.97 at the most recent close of the market. An investor can expect a potential return of 122.07% based on the average WVE price forecast.
Analyzing the WVE fundamentals
Wave Life Sciences Ltd [NASDAQ:WVE] reported sales of 93.95M for the trailing twelve months, which represents a drop of -55.82%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -1.53%, Pretax Profit Margin comes in at -1.38%, and Net Profit Margin reading is -1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.78 and Total Capital is -0.87. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.82 points at the first support level, and at 9.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.15, and for the 2nd resistance point, it is at 10.32.
Ratios To Look Out For
For context, Wave Life Sciences Ltd’s Current Ratio is 2.56. In addition, the Quick Ratio stands at 2.56 and the Cash Ratio stands at 2.39. Considering the valuation of this stock, the price to sales ratio is 16.89, the price to book ratio is 11.14.
Transactions by insiders
Recent insider trading involved Verdine Gregory L., Director, that happened on Aug 22 ’25 when 10000.0 shares were sold. President and CEO, BOLNO PAUL completed a deal on Aug 22 ’25 to sell 0.22 million shares. Meanwhile, Director PAUL BOLNO bought 0.22 million shares on Aug 22 ’25.
